Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background and aims The objective of this study was to investigate the effects of semaglutide, a long acting glucagon-like peptide-1 receptor agonist, on atherosclerotic inflammation and calcification using a multimodality positron emission tomography and computed tomography (PET/CT) approach. Methods Atherosclerotic New Zealand White rabbits were randomized to an intervention- (n = 12) or placebo group (n = 11) receiving either semaglutide or saline-placebo. PET/CT imaging was done before and after 16-weeks of intervention. Three different radiotracers were used: [ 64 Cu]Cu-DOTATATE for imaging of activated macrophages, [ 18 F]FDG imaging cellular metabolism and [ 18 F]NaF PET visualizing micro-calcifications. Tracer uptake was quantified by maximum standardized uptake value (SUV max ) and target-to-background-ratio (TBR max ). Animals were euthanized for autoradiographic imaging and histological analyses. Results A reduction in activated macrophage tracer-uptake was observed in the semaglutide group (SUV max : p = 0.001 and TBR max : p = 0.029). When imaging cellular metabolism, an attenuation of SUV max and TBR max was observed in the semaglutide group ( p = 0.034 and p = 0.044). We found no difference in uptake of the micro-calcification tracer between the two groups (SUV max : p = 0.62 and TBR max : p = 0.36). Values of macrophage density in the vessel wall were significantly correlated with SUV max values of the activated macrophage (r = 0.54, p = 0.0086) and cellular metabolism tracers (r = 0.51, p = 0.013). Conclusions Semaglutide decreased vascular uptake of tracers imaging activated macrophages and cellular metabolism but not micro-calcifications compared to a saline placebo. This supports the hypothesis that semaglutide reduces atherosclerotic inflammation by means of decreased activated macrophage activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Monocyte-macrophages and T cells in atherosclerosis
Tabas, I., & Lichtman, A. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.008 · Cited by 646
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Fan, J., Kitajima, S., Watanabe, T., Xu, J., Zhang, J., Liu, E., & Chen, Y. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.009 · Cited by 333
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259
Cited by
Malavazos, A. E., Iacobellis, G., Dozio, E., Basilico, S., Di Vincenzo, A., Dubini, C., Menicanti, L., Vianello, E., Meregalli, C., Ruocco, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad050 · Cited by 100
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Positron emission tomography (PET) imaging of rabbits identified that semaglutide reduced macrophage activation and metabolism in the aortic wall by using [ 64 Cu]Cu-DOTATATE and [18F]FDG radiotracers, respectively [139].”
MethodChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Metadata
- Authors
- Jensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjaer, A.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 352
- Pages
- 88-95
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4223512257
- Cited by
- 49
- References
- 12
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2022.03.032
- The paper
- Jensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjaer, A. (2022). Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2022.03.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.